CHICAGO - Researchers reported that 14 patients receiving crizotinib (Xalkori) treatment, eight patients with the LEP drug response, four patients with disease stability control, while the drug targeting point mutations the ROS1 mutations occur in 1% to 2% of non-small cell lung cancer.The most common side effects of the drug is a mild visual impairment, mild visual impairment, side effects occurred in almost all patients. In short,-crizotinib of adverse drug reactions in this study is consistent with the clinical assessment of other LEPR relevant crizotinib. Massachusetts General Hospital in Boston, Shaw said, the ROS1 the rearrangement led to the emergence of a particular subtype of non-small cell lung cancer. Crizotinib show that marks the progress ROS1 positive non-small cell lung cancer patients with anti-tumor activity. These data confirm the therapeutic targets of ROS1 in the treatment of LGALS1 lung cancer. Shaw added that some patients have dramatic responses, is associated with improvement of symptoms when treatment is started and the next few weeks the reduction of the tumor tissue. rizotinib In addition to inhibition of ROS1, also inhibited MEK and ALK. The ROS1 recently been seen as a special subtype of non-small cell lung cancer.
The drug has been approved for locally LGALS14 advanced and metastatic ALK-positive non-small cell lung cancer patients. Shaw said: "Although ROS1 with non-small cell lung cancer linked to or has recently happened, but for the understanding of the ROS1 had already started 20 years ago, but for ROS1 the normal function is not very clear at the cellular level , ROS1 to activate the signaling pathway is also shared with other tyrosine kinase receptors achieved in LGALS2 cancer patients, the chromosome rearrangement is the primary mechanism of ROS1 activation of proto-oncogene form of ROS1 as activation and malignant tumor formation related to the next signaling pathway material. crizotinib cMET inhibitor initially, and then found that the inhibitory activity can also inhibit several other tyrosine kinases, including ROS1. In the preclinical study of crizotinib show confrontation the ROS1 driven tumor cell activity, confirmed the feasibility of a clinical trial. By fluorescence in situ hybridization analysis, the researchers screened out the ROS1 positive metastatic non-small cell lung cancer patients, and given an initial dose 250mgbid the standard treatment in order to identify patients with ALK-positive tumors. Shaw said that so far has treated 15 patients, there are 12 patients in the treatment of 14 patients in the evaluation of treatment response. All of these patients have adenocarcinoma histology reports, but one were non-smokers, 12 patients with metastases received a 1 or a number of treatment. Cohort study showed that patients reflect the drug accounted for 57.1%, and the treatment, the median time of 25.7 weeks. The disease control rate was 79%, including 4 disease have been reached or more than 8 weeks in patients with stable. Apart from a slight visual impairment, the most common adverse reactions (≥ 10% of patients) had elevated liver enzymes, diarrhea, hypophosphatemia, angioneurotic edema, taste perversion, nausea, vomiting, alkaline phosphatase increased, neutropenia, sinus bradycardia. ASCO another study report (ASCO2012. Abstract 7505) pointed out that the findings add another non-small cell lung cancer mutation problem, related to the problem of non-small cell lung cancer the MEK, ALK FGFR1PTEN, and, of PIK3CA and DDR2. short, 63% of squamous cell carcinoma patients point mutations can be seen as a therapy target. In the discussion of Shaw's speech, MD GregoryRiely comes to non-small cell lung cancer are from a single entity as a heterogeneous disease-related changes in multiple gene mutations, and this change also occurs in clinical practice. Riely Memorial Sloan - Kettering Cancer Center in New York said: "by smoking history, race, age and other factors is difficult to identify these patients. We really need to go to the screening of all patients. Reference to the study" a significant "response rate, Riely said he intends to use each ROS1-positive patients crizotinib treatment Riely said," I hope the insurance company can participate, because it is clear, these data are correct. "